About Exelixis
Exelixis is a publicly listed company based in San Francisco (United States) founded in 1994. Small molecule drugs for cancer treatment are developed. The company has 1,150 employees. Exelixis has completed 3 acquisitions, including Agritope, X-Ceptor Therapeutics and Xceptor. Its website exelixis.com draws about 39 thousand monthly visits. Exelixis offers products and services including CABOMETYX and COMETRIQ. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Exelixis, Inc. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Exelixis was founded in 1994 in San Francisco, United States, within the biotechnology sector. Small molecule therapeutics for oncology are developed, with a focus on inhibiting key enzymes and proteins. Cabozantinib, the lead product, targets receptor tyrosine kinases for metastatic medullary thyroid cancer treatment. Cobimetinib addresses melanoma, while XL888 functions as an oral HSP90 inhibitor affecting regulatory proteins. Operations center on advancing cancer therapies through clinical and preclinical research.
- Headquarters San Francisco, United States
- Employees 1,150
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website exelixis.com
- Social LinkedIn X Facebook
- Legal Name Exelixis, Inc.
Products & Services of Exelixis
Exelixis offers a comprehensive portfolio of products and services, including CABOMETYX and COMETRIQ.
Treatment for advanced neuroendocrine tumors and other cancers.
Cabozantinib-based therapy for specific cancer types.
Funding Insights of Exelixis
- Total Rounds 6
- Last Round Grant — $366,835
- First Round $848,057
(Aug 2005)
- Investors Count 3
All 6 funding rounds of Exelixis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $366,835 | Grant | – | – | |
| Jun 2020 | $159,709 | Grant | – | – | |
| Aug 2016 | $168M | Post-IPO | – | – | – |
| Sep 2009 | $224,131 | Grant | – | – | |
| Aug 2009 | $2.1M | Grant | – | – | |
| Aug 2005 | $848,057 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Exelixis
Exelixis has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and OSTI.GOV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Scientific and technical information is managed and disseminated by OSTI.GOV. | osti.gov | Oak Ridge, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Exelixis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exelixis
288 people are tracked at Exelixis (180 in leadership, 10 in board & advisors, 98 in team); the tracked headcount is 1,150.
| Name | Role | Group |
|---|---|---|
Michael M. Morrissey | President & CEO | Leadership |
Aaliyah Mumin | Senior HR Business Partner | Leadership |
Himabindu Gopisetti | Associate Director, Program Management CMC Biologics | Leadership |
Leo Kirkovsky | Senior Director | Leadership |
Aiwen D. | Associate Director, Translational Medicine | Leadership |
Linda R. Ibe | Executive Director, Total Rewards | Leadership |
Tracye Laun | Head Of Learning And Development | Leadership |
Whitney Brenner | Director, Marketing - Key Customer Team | Leadership |
Yushma Bhurruth-Alcor | Director, Medicinal Chemistry | Leadership |
Chris Senner | Executive Vice President And CFO | Leadership |
Ahmed Othman | Vice President, Clinical Pharmacology, Pharmacometrics, DMPK & Bioanalysis | Leadership |
Sang Kim | Associate Director Of Digital Marketing | Leadership |
Yinzi Liu | Director Of Corporate Finance, Bd, M&a | Leadership |
Andy Simmons | Vice President, Translational Medicine | Leadership |
Michelle Liu | Senior Director, Commercial Strategy And Planning | Leadership |
Jennifer Ormerod | Scientific Communications Director - Pipeline Strategy | Leadership |
Michael Martinelli | Vice President | Leadership |
Geoff Stone | Director, Immuno-oncology | Leadership |
Varant Shirvanian | Director, Investor Relations | Leadership |
Claudia V. Garcia | Senior Director And Counsel, Commercial Legal Affairs | Leadership |
268 more people are available in the full profile.
Complete people profiles for Exelixis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Exelixis
Exelixis is a publicly listed company on the NASDAQ with ticker symbol EXEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Apr 2000
- Listed onNASDAQ: EXEL
- Listed entityExelixis, Inc.
- Exchange sectorHealth technology
- ISINUS30161Q1040
- Share price$59.51 (-0.52% on the day) · 2026-10-13
- Market capitalisation$14.75B
- Price to earnings18.7
- EPS (diluted, trailing year)$3.18
- Volume (last session)2,624,725
Financials of Exelixis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.32B | $782.6M | $921.8M |
| 2024 | $2.17B | $521.3M | $718.8M |
| 2023 | $1.83B | $207.8M | $196.6M |
| 2022 | $1.61B | $182.3M | $222.4M |
| 2021 | $1.43B | $231.1M | $300.3M |
Detailed financial statements for Exelixis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exelixis
Exelixis has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Agritope, X-Ceptor Therapeutics and Xceptor.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Data automation software is provided for financial markets operations. | xceptor.com | London, United Kingdom | 2003 | Sep 2004 | $22.3M | |
Nuclear receptor modulating small molecule drugs for metabolism and cardiovascular diseases | x-ceptor.com | San Diego, United States | 1999 | Sep 2004 | $22.3M | |
Developer of transgenic varieties of fruit and vegetable crops | agritope.com | Portland, United States | 1997 | Sep 2000 | $68M |
Complete acquisition details for Exelixis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Exelixis
7 dated milestones of Exelixis across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Exelixis is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Agritope.
- Acquisition Acquires Xceptor.
- Acquisition Acquires X-Ceptor Therapeutics.
- Funding First funding round of $848K.
- Funding Latest funding round, Grant, of $367K.
Competitors of Exelixis
Exelixis has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Exelixis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Exelixis
The website of Exelixis (exelixis.com) receives about 39.1K visits a month and ranks #1,001,350 among all websites worldwide, #1,229 in Biotechnology and Pharmaceuticals.
- Monthly visits39.1K
▲ 48.6% vs previous month
- Unique visitors10.2K
per month
- Global rank#1,001,350
among all websites
- Category rank#1,229
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit2.4
- Average visit1 min 07 sec
- DevicesDesktop 53% · Mobile 47%
Websites whose visitors overlap most with Exelixis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cytokinetics.com | 100% | 25.3K | #1,072,700 | View details | |
| medivation.com | 99% | View details | |||
| ariad.com | 95% | View details | |||
| arraybiopharma.com | 86% | View details | |||
depomed.com | depomed.com | 85% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 32 similar websites and full traffic analytics for Exelixis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 32 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Exelixis (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exelixis
Complete news archive for Exelixis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exelixis
Exelixis was founded in 1994 and raised its 1st funding round 11 years after it was founded.
Exelixis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Exelixis has 1,150 employees.
Annual revenue of Exelixis is $2.32B as on Dec 31, 2025.
Exelixis was founded in 1994 in San Francisco, United States, within the biotechnology sector. Small molecule therapeutics for oncology are developed, with a focus on inhibiting key enzymes and proteins. Cabozantinib, the lead product, targets receptor tyrosine kinases for metastatic medullary thyroid cancer treatment. Cobimetinib addresses melanoma, while XL888 functions as an oral HSP90 inhibitor affecting regulatory proteins. Operations center on advancing cancer therapies through clinical and preclinical research.
Exelixis's top competitors include C4 Therapeutics, Erasca and MiRagen.
Exelixis offers CABOMETYX and COMETRIQ.
Yes, Exelixis is publicly traded on NASDAQ under the ticker symbol EXEL.
Exelixis has made 3 acquisitions, including Agritope, X-Ceptor Therapeutics, and Xceptor.
Exelixis has 3 investors. Key investors include HHS, European Union, and OSTI.GOV.
Exelixis operates through Exelixis, Inc..